Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma

Meijer, R. J. G. M.; Postma, Dirkje S.; Kauffman, Hf; Arends, Lidia R.; Koeter, Gh; Kerstjens, Huib A. M.

doi:10.1046/j.1365-2222.2002.01412.x

Cited by 99 publications

(79 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(15) The authors suggested that higher IgE levels indicate the presence of Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma 27 mation, adds to this, whereas ECP provides no additional information. (27) The peripheral blood eosinophil count, the serum ECP concentration, and the ECP/eosinophil ratio have been shown to be significantly higher during acute asthma exacerbations than during clinical remission. (28) Other authors reported that a high blood eosinophil count at baseline and an increase in sputum eosinophil count after the reduction of corticosteroids were predictors of loss of asthma control.…”

Section: Resultsmentioning

confidence: 99%

Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma

Razi

Moosavi

2010

J. bras. pneumol.

View full text Add to dashboard Cite

Objective: To determine whether serum total IgE levels and total eosinophil counts have any relationship with the response to routine pharmacological treatment in patients with acute asthma. Methods: A cross-sectional study involving 162 patients with acute asthma. Serum total IgE levels, peripheral blood cell counts and eosinophil counts were determined. The treatment was adjusted for each patient according to the severity of asthma. Spirometry was performed at baseline and two weeks after the treatment. The patients were divided into two groups: high IgE (≥100 IU/mL) and low IgE (<100 IU/mL). We compared the two groups in terms of the relationships between baseline values and final values (percentage change) for the following parameters: FEV 1 , FVC, FEF 25-75% , peripheral white blood cell counts and eosinophil counts. Results: There were no significant differences between the groups regarding the percentage changes of the studied parameters. Nor were there significant differences between the groups regarding FEV 1 , FVC, and FEF 25-75% (% of the predicted values) at baseline. Conclusions: On the basis of these findings, we conclude that serum total IgE levels, peripheral white blood cell counts and eosinophil counts cannot predict the response to the pharmacological treatment of patients with acute asthma.Keywords: Asthma/drug therapy; Eosinophils; Immunoglobulin E Resumo Objetivo: Determinar se há uma relação dos níveis de IgE total no soro e das contagens de eosinófilos com a resposta à farmacoterapia de rotina em pacientes com asma aguda. Métodos: Estudo transversal com 162 pacientes com asma aguda. Foram determinados os níveis séricos de IgE total, as contagens de células no sangue periférico e as contagens de eosinófilos. O tratamento foi ajustado individualmente de acordo com a gravidade da asma. Foi realizada espirometria antes do início do tratamento e duas semanas após seu término. Os pacientes foram divididos em dois grupos: alto nível de IgE (≥ 100 UI/mL) e baixo nível de IgE (< 100 UI/mL). Foram comparadas entre os dois grupos as relações das determinações basais e das alterações em percentual dos seguintes parâmetros: VEF, CVF, FEF 25-75% , contagem de células brancas no sangue periférico e contagem de eosinófilos. Resultados: Não houve diferenças significativas entre os grupos em relação às alterações em percentual dos parâ-metros estudados. Tampouco houve diferenças significativas entre os grupos em relação aos valores basais de VEF, CVF e FEF 25-75% , em % do predito. Conclusões: Com base nesses achados, concluímos que os níveis séricos de IgE total, as contagens de células brancas no sangue periférico e as contagens de eosinófilos não são preditores do tratamento farmacológico de pacientes com asma aguda.

show abstract

Section: Resultsmentioning

confidence: 99%

Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma

Razi

Moosavi

2010

J. bras. pneumol.

View full text Add to dashboard Cite

show abstract

“…In COPD and asthma, eosinophilic rather than neutrophilic inflammatory activity predicts favourable response to ICS [5,[8][9][10]. Nitric oxide output is associated mainly with eosinophilic airway inflammation [31][32][33], whereas LTB 4 (chemotactic factor for neutrophils) and 8-isoprostane (marker of lipid peroxidation) are associated with neutrophilic inflammation [18,23].…”

Section: Discussionmentioning

confidence: 99%

“…ICS are less effective in COPD than in asthma, but some subjects with COPD gain from ICS by improvement in their lung function and health status [3]. High levels of markers of eosinophilic inflammation, like exhaled NO concentration [4] and sputum eosinophils [5], predict favourable response to ICS in asthma, and these markers may also be useful in titrating the ICS dose in long-term asthma management [6,7]. There are also some studies showing that high levels of sputum eosinophils in COPD predict favourable response to a short course of oral prednisolone [8] or ICS [9,10], but the role of exhaled NO or inflammatory markers in exhaled breath condensate (EBC) in predicting response to ICS in COPD is not known.…”

mentioning

confidence: 99%

Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD

Lehtimäki

Kankaanranta²,

Saarelainen³

et al. 2009

European Respiratory Journal

View full text Add to dashboard Cite

High levels of exhaled nitric oxide (NO) predict favourable response to inhaled corticosteroids in asthma, but the ability of exhaled NO or inflammatory markers in exhaled breath condensate (EBC) to predict steroid responsiveness in chronic obstructive pulmonary disease (COPD) is not known.We measured alveolar and bronchial NO output, levels of leukotriene B 4 (LTB 4 ), cysteinyl leukotrienes (cysLTs) and 8-isoprostane in EBC, spirometry, body plethysmography and symptoms in 40 subjects with COPD before and after 4 weeks of treatment with inhaled fluticasone (500 mg b.i.d.).Five subjects (12.5%) with COPD had significant improvement in lung function during fluticasone treatment, whereas 20 subjects (50%) had significant decrease in symptoms. High baseline bronchial NO flux was associated with higher increase in forced expiratory volume in 1 s to forced vital capacity ratio (r50.334, p50.038) and more symptom relief (r5 -0.317, p50.049) during the treatment. Baseline EBC levels of LTB 4 , cysLTs or 8-isoprostane were not related to response to fluticasone treatment. Inhaled fluticasone decreased bronchial NO flux but not alveolar NO concentration or markers in EBC.High levels of bronchial NO flux are related to symptom relief and improvement of airway obstruction during treatment with inhaled fluticasone in COPD. Markers of inflammation or oxidative stress in EBC are not related to steroid responsiveness in COPD.

show abstract

“…Another study from LITTLE et al [22] demonstrated that sputum eosinophilia (w3%) predicted improvement in FEV1 in asthmatic subjects already on inhaled steroids (median dose equivalent to 800 mg of inhaled beclomethasone) after treatment with oral prednisolone (30 mg?day -1 ) for 2 weeks with a sensitivity of 54% and specificity of 76%. Subsequently, MEIJER et al [23] examined the value of clinical parameters (FEV1, the provocative concentration of methacholine causing a 20% fall in the FEV1 (PC20) and asthma quality-of-life questionnaire), and inflammatory markers in blood and sputum (eosinophils and eosinophil cationic protein (ECP)) or exhaled nitric oxide to predict benefit from corticosteroid treatment. In this double-blind, double-dummy, parallel-group study, 120 subjects with uncontrolled asthma were randomised to receiving a 2-week treatment with either prednisolone 30 mg?day -1 , fluticasone propionate 1,000 mg b.i.d.…”

mentioning

confidence: 99%

Is sputum eosinophilia a good or poor predictor of benefit from inhaled corticosteroid therapy in asthma?

Pizzichini¹

2002

Eur Respir J

View full text Add to dashboard Cite

Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma

Cited by 99 publications

References 38 publications

Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma

Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma

Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD

Is sputum eosinophilia a good or poor predictor of benefit from inhaled corticosteroid therapy in asthma?

Contact Info

Product

Resources

About